Net Spending On Retail Specialty Drugs Grew Rapidly, Especially For Private Insurance And Medicare Part D
| Autor: | Steven C. Hill, Yao Ding, G. Edward Miller |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Actuarial science
ComputingMilieux_THECOMPUTINGPROFESSION business.industry 030503 health policy & services Health Policy media_common.quotation_subject MEDLINE Specialty ComputerApplications_COMPUTERSINOTHERSYSTEMS ComputingMilieux_LEGALASPECTSOFCOMPUTING Pharmacy Payment 03 medical and health sciences 0302 clinical medicine Medicare Part D 030212 general & internal medicine Business Private insurance 0305 other medical science media_common |
| Zdroj: | Health Affairs. 39:1970-1976 |
| ISSN: | 1544-5208 0278-2715 |
| DOI: | 10.1377/hlthaff.2019.01830 |
| Popis: | Specialty drugs are expensive, but spending on specialty drugs is difficult to measure because of proprietary rebate payments by manufacturers to insurers, pharmacy benefit managers, and state Medi... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|